Search

Displaying results 881 - 890 of 5089 in total
  1. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    [A275338] Depemokimab blocks interleukin-5 (IL-5), a key cytokine that regulates eosinophil maturation, survival, and recruitment.

  2. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    Marketed as the product Ruconest (FDA), this drug is indicated for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults. … Down-stream effects of the lack of enzyme inhibition by C1 esterase inhibitor results in swelling due to leakage of fluid from blood vessels into connective tissue and consequently the presentation of

    Products: RUCONEST 2100 U IV ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADET
  3. Drug

    Ethinylestradiol

    go.drugbank.com/drugs/DB00977
    ApprovedInvestigational

    Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was developed in an effort to create an estrogen with greater oral bioavailability. These properties were achieved by the substitu...

    Mixtures: PIL KB HARMONIS, PIL KB I KOMBINASI
  4. Drug

    Sucrose

    go.drugbank.com/drugs/DB02772
    ApprovedInvestigational

    A nonreducing disaccharide composed of glucose and fructose linked via their anomeric carbons.

    Synonyms: 1-alpha-D-Glucopyranosyl-2-beta-D-fructofuranoside
  5. Drug

    Dexchlorpheniramine maleate

    go.drugbank.com/drugs/DB09555
    Approved

    Dexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.

    Mixtures: Polytussin DM, WesTussin DM
  6. Drug

    Nicorandil

    go.drugbank.com/drugs/DB09220
    ApprovedInvestigationalWithdrawn

    Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular

  7. Drug

    Buprenorphine

    go.drugbank.com/drugs/DB00921
    ApprovedIllicitInvestigationalVet approved

    [A186263,A186266,A186269] Buprenorphine acts as a partial mu-opioid receptor agonist with a high affinity for the receptor, but lower intrinsic activity compared to other full mu-opioid agonists such … Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.

    Mixtures: Bupensan Duo 4 mg/1 mg-Sublingualtabletten, Bupensan Duo 8 mg/2 mg-Sublingualtabletten
  8. Drug

    Alpha-1-proteinase inhibitor

    go.drugbank.com/drugs/DB00058
    ApprovedInvestigational

    Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.

  9. Drug

    Synthetic Conjugated Estrogens, A

    go.drugbank.com/drugs/DB09317
    Approved

    However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control

  10. Drug

    Testosterone undecanoate

    go.drugbank.com/drugs/DB13946
    ApprovedInvestigational

    [L35970] It was developed via fatty acid esterification of testosterone in order to achieve orally administer testosterone.